Watermark
  Back to Search Results

BGB-A317-A1217-203

Completed

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-A317-A1217-203

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04732494

EudraCT Number Info icon SVG graphic used for tooltips or additional information.

2020-004658-32

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20213241/CTR20210243

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Study Protocol Statistical Analysis Plan